Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept Treatment in Exudative Maculopathies (RAP, PED, Hemorrhagic CNV, PCV)
2014-002384-15Phase 4Completed
- Sponsor
- Department of Ophthalmology, Medical University of Vienna
- Start
- Sep 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in Exudative Maculopathy, polypoidal choroidal vasculopathy (PCV), Subretinal neovascularization and 2 more, sponsored by Department of Ophthalmology, Medical University of Vienna. Primary endpoint: Visual acuity. Started Sep 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
Exudative Maculopathypolypoidal choroidal vasculopathy (PCV)Subretinal neovascularizationretinal angiomatous proliferation (RAP)pigment epithelium detachment (PED)
Beyond the preview
Go deeper on 2014-002384-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002384-15.